IL141686A0 - Methods of treating hypertension and compositions for use therein - Google Patents

Methods of treating hypertension and compositions for use therein

Info

Publication number
IL141686A0
IL141686A0 IL14168699A IL14168699A IL141686A0 IL 141686 A0 IL141686 A0 IL 141686A0 IL 14168699 A IL14168699 A IL 14168699A IL 14168699 A IL14168699 A IL 14168699A IL 141686 A0 IL141686 A0 IL 141686A0
Authority
IL
Israel
Prior art keywords
methods
compositions
treating hypertension
factor
vascular permeability
Prior art date
Application number
IL14168699A
Other languages
English (en)
Original Assignee
Scios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc filed Critical Scios Inc
Publication of IL141686A0 publication Critical patent/IL141686A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14168699A 1998-09-09 1999-09-09 Methods of treating hypertension and compositions for use therein IL141686A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US12640699P 1999-03-26 1999-03-26
US12661599P 1999-03-27 1999-03-27
PCT/US1999/020481 WO2000013703A2 (en) 1998-09-09 1999-09-09 Methods of treating hypertension and compositions for use therein

Publications (1)

Publication Number Publication Date
IL141686A0 true IL141686A0 (en) 2002-03-10

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14168699A IL141686A0 (en) 1998-09-09 1999-09-09 Methods of treating hypertension and compositions for use therein
IL14168799A IL141687A0 (en) 1998-09-09 1999-09-09 Treatment of microvascular angiopathies

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL14168799A IL141687A0 (en) 1998-09-09 1999-09-09 Treatment of microvascular angiopathies

Country Status (13)

Country Link
US (3) US6352975B1 (https=)
EP (2) EP1112083B1 (https=)
JP (2) JP2002532382A (https=)
AT (2) ATE260675T1 (https=)
AU (2) AU5910599A (https=)
BR (2) BR9913533A (https=)
CA (2) CA2340320C (https=)
DE (2) DE69912815T2 (https=)
DK (2) DK1109571T3 (https=)
ES (2) ES2216630T3 (https=)
IL (2) IL141686A0 (https=)
PT (2) PT1109571E (https=)
WO (2) WO2000013702A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216630T3 (es) * 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
IL148674A0 (en) * 1999-11-02 2002-09-12 Genentech Inc Modulation of enos activity and therapeutic uses thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US7820178B2 (en) 2001-08-01 2010-10-26 University of Brisol VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
WO2003015605A2 (en) * 2001-08-20 2003-02-27 University Of Virginia Patent Foundation Use of s-nitrosothiol signaling to treat disordered control of breathing
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
EP1964568B1 (en) * 2005-08-31 2014-03-26 National University Corporation Kagawa University Utilization of hypertension/hypercardia-preventing effect of d-allose
ES2600781T3 (es) 2008-12-04 2017-02-10 Curna, Inc. Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
AU2018244776B2 (en) 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
WO1990011084A1 (en) 1989-03-24 1990-10-04 The Regents Of The University Of California Endothelial cell growth factor, isolation and expression
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
EP0941116B1 (en) * 1996-11-01 2005-01-19 Ark Therapeutics Limited Use of vegf for the manufacture of a medicament for the treatment or prevention of intimal hyperplasia and delivery device
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
ES2216630T3 (es) * 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.

Also Published As

Publication number Publication date
JP2002524421A (ja) 2002-08-06
WO2000013702A3 (en) 2000-09-08
DE69915310D1 (de) 2004-04-08
ES2216630T3 (es) 2004-10-16
ES2211165T3 (es) 2004-07-01
CA2340320A1 (en) 2000-03-16
EP1112083B1 (en) 2003-11-12
DE69915310T2 (de) 2005-03-10
DK1112083T3 (da) 2004-03-08
AU5910599A (en) 2000-03-27
DK1109571T3 (da) 2004-06-21
WO2000013703A2 (en) 2000-03-16
WO2000013702A9 (en) 2000-10-19
BR9913564A (pt) 2001-05-22
EP1109571A2 (en) 2001-06-27
CA2340728A1 (en) 2000-03-16
ATE253934T1 (de) 2003-11-15
US6352975B1 (en) 2002-03-05
IL141687A0 (en) 2002-03-10
ATE260675T1 (de) 2004-03-15
WO2000013703A3 (en) 2000-07-06
EP1112083A2 (en) 2001-07-04
US20040224885A1 (en) 2004-11-11
DE69912815D1 (de) 2003-12-18
WO2000013702A2 (en) 2000-03-16
WO2000013703A9 (en) 2000-06-02
BR9913533A (pt) 2001-06-05
PT1112083E (pt) 2004-03-31
PT1109571E (pt) 2004-05-31
CA2340728C (en) 2007-11-27
EP1109571B1 (en) 2004-03-03
JP2002532382A (ja) 2002-10-02
CA2340320C (en) 2006-11-14
AU6028599A (en) 2000-03-27
US20020193288A1 (en) 2002-12-19
DE69912815T2 (de) 2004-10-21

Similar Documents

Publication Publication Date Title
IL141686A0 (en) Methods of treating hypertension and compositions for use therein
PL328858A1 (en) Immunogenous peptides
WO1997045137A8 (en) Methods and compositions useful for inhibition of angiogenesis
MY117032A (en) A novel compound form.
YU15299A (sh) Farmaceutski sastavi
PL349028A1 (en) Cancer treatment composition and method using natural plant essential oils
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
BG101139A (en) Heteroatoms-containing cyclopentanopyridyloxazolidinons
MXPA01006099A (es) Metodos y composiciones para reducir las permeabilidades de zonas subterraneas.
MX9604145A (es) Metodos y composiciones utiles para la inhibicion de angiogenesis.
WO1999004752A3 (en) Methods for treating skin pigmentation
AU2212299A (en) Compositions and methods for the treatment of tumor
HUP0104688A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
IL131701A (en) Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents
ZA97252B (en) Compositions for the prevention and treatment of osteoporosis.
IL141426A0 (en) Compositions and methods for the treatment of tumor
IL143212A0 (en) Compositions and methods for the treatment of tumor
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
EP1447089A3 (en) Methods of treating hypertension and compositions for use therein
BG104914A (en) Paroxetine maleate
ZA988293B (en) Compositions and methods for the treatment of tumor.
KR100511819B1 (en) Compositions and Methods for the Treatment of Tumor
UA32316A (uk) Спосіб лікування жінок з патологічним клімаксом
GB0021287D0 (en) Composition and method for the treatment of cancers
UA32314A (uk) Спосіб лікування некротичного панкреатиту